FDA OKs new multiple sclerosis drug

WASHINGTON — The Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

The twice-a-day capsules, called Tecfidera, offer a new option for multiple sclerosis, a debilitating disease in which the body attacks its own nervous system. Cambridge, Mass.-based Biogen Idec already sells two other drugs for the disease, but both require injections.

There is no cure for multiple sclerosis and most patients experience relapses of symptoms, including loss of balance, weakness in arms and legs, and blurred vision. Over time patients usually become weaker and less coordinated. More than 2 million people worldwide have the disease, with about 400,000 of them in the U.S., according to Biogen.

The FDA said it approved Tecfidera based on two studies showing patients taking the drug had fewer relapses than patients taking a dummy pill.

The approval gives Biogen a new product in an increasingly crowded field of multiple sclerosis drugs.

The biotech drugmaker already sells the once-a-week multiple sclerosis injection Avonex. It also markets the once-a-month injection Tysabri through a partnership with Elan Corp. PLC of Ireland. However, Tysabri’s severe side effects have curtailed its use.

Tecfidera is designed to be taken orally, which could make it a preferred option for patients and doctors.

A Biogen executive said Wednesday that its three drugs would be used to treat different groups of patients.

“Multiple sclerosis is a reasonably complex disease and we think there are a lot of needs out there,” said Tony Kingsely, a vice president at Biogen. “By having three drugs out there I think we can address a lot of those needs.”

Kinglsey said the company will announce the pricing of the drug when it begins shipping in the next week.

Novartis launched the first pill-based multiple sclerosis drug, Gilenya, in March 2011. Sanofi won FDA approval for a second pill, its drug Aubagio, last September.

The top-selling drug for the disease worldwide is Copaxone, which is made by Teva Pharmaceutical Industries. That injection had sales of nearly $4 billion last year, according to Teva’s latest financial report.

Avonex and Tysabri had annual sales of $2.7 billion and $1.5 billion in 2011, the most recent year for which Biogen has reported annual sales.

Biogen Idec Inc. shares rose $5.59, or 3.2 percent, to close Wednesday at $182.68.

More in Local News

A customer walks away after buying a hot dog from a vendor on 33rd St and Smith Street near the Everett Station on Friday. The Everett Station District Alliance pictures the area east of Broadway and south of Hewitt Avenue as a future neighborhood and transit hub that could absorb expected population growth. (Andy Bronson / The Herald)
How can Everett Station become a vibrant part of city?

A neighborhood alliance focused on long-term revitalization will update the public Tuesday.

Man arrested after police find van full of drugs, cash and guns

An officer on patrol noticed a vehicle by itself in the middle of a WinCo parking lot at 2 a.m.

After work to address issues, Lynnwood gets clean audit

The city has benefited from increased revenues from sales tax.

Bolshevik replaces BS in Eyman’s voters pamphlet statement

The initiative promoter also lost a bid to include a hyperlink to online coverage of the battle.

Man with shotgun confronts man on toilet about missing phone

Police say the victim was doing his business when the suspect barged in and threatened him.

Detectives seek suspect in woman’s homicide

Alisha Michelle Canales-McGuire was shot to death Wednesday at a home south of Paine Field.

Car crashes near Everett after State Patrol pursuit

The driver and a second person in the car suffered injuries.

Smith Island habitat restoration cost to rise $1.2 million

The project is intended to increase survival rates for juvenile chinook salmon.

Jim Mathis, the Vietnam veteran whose Marysville garden was recently featured in The Herald, died Wednesday. Mathis, who suffered from PTSD and cancer, found solace in his beautiful garden. (Dan Bates / The Herald)
Vietnam veteran Jim Mathis found peace in his garden

The Marysville man who served two tours died Wednesday after suffering from cancer and PTSD.

Most Read